Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer

Seong-Gyu Ko

Status and phase

Unknown

Phase 3

Phase 2

Conditions

Postoperative Cough

Lung Cancer

Treatments

Drug: Placebo

Drug: Maekmoondong-tang

Study type

Interventional

Funder types

Other

Identifiers

NCT03384667

ISEE_MMDT_2017

Details and patient eligibility

About

The aim of the present study is to evaluate the efficacy and safety of Maekmoondong-tang on post-operative cough in patients with lung cancer. A randomized, double-blind, placebo-controlled trial will be conducted.

Enrollment

96 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults over 20 years old.
Patients undergone segmentectomy or lobectomy for lung cancer within 1 month
Patients who do not or poorly respond to one week administration of common antitussive agents.
Eastern Cooperative Oncology Group(ECOG) 0 to 2
Participant is willing and able to give informed consent for participation in the study

Exclusion criteria

Patients undergoing adjuvant chemotherapy.
Patients who have been diagnosed with acute respiratory disease within 1 month.
Patients who have been diagnosed with bronchial asthma or bronchiectasis within 1 year
Patients taking Angiotensin Converting Enzyme Inhibitor
Patients with pseudoaldosteronism.
Participants who have known prior hypersensitivity to any investigational product component
Patient with acute or chronic infections requiring treatment (active HAV, HBV, HCV, HIV, TB)
Pregnant or lactating females
Women of childbearing potential
Patient who do not agrees to use effective means of contraception and not to donate sperm during the trial and up to 1 month after final administration
Patient who participated other clinical trials of medicine or medical devices within 1 month
Individuals who are judged inappropriate for the study by investigator